$136.25 1.7%
CRL Stock Price vs. AI Score
Data gathered: May 29

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Charles River Laboratories (CRL)

Analysis generated August 19, 2024. Powered by Chat GPT.

Charles River Laboratories International, Inc. (NYSE: CRL) is a global provider of essential products and services to expedite the discovery, early-stage development, and safe manufacture of novel drugs and therapeutics. They operate through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (MS). With an extensive portfolio of services, Charles River Laboratories aims to enhance the productivity and efficiency of pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide.

Read full AI stock Analysis

Stock Alerts - Charles River Laboratories (CRL)

company logo Charles River Laboratories | May 21
AI Score is down by 21.4% in the last couple of days.
company logo Charles River Laboratories | May 20
Employee Rating is up by 3.2% over the last month.
company logo Charles River Laboratories | May 16
Insider Alert: MASSARO GEORGE is selling shares
company logo Charles River Laboratories | May 10
Rob Bresnahan (member of U.S. congress) is buying shares

Download our app to get future alerts delivered in real-time.

About Charles River Laboratories

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.


Charles River Laboratories
Price $136.25
Target Price Sign up
Volume 600,730
Market Cap $6.81B
Year Range $99.75 - $220.69
Dividend Yield 0%
PE Ratio 592.3
Analyst Rating 7% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '25984M666M318M25M184M2.340
Q4 '241B718M278M-216M-86M2.660
Q3 '241.01B661M349M69M210M2.590
Q2 '241.03B691M335M90M239M2.800
Q1 '241.01B691M320M67M219M2.270

Insider Transactions View All

MASSARO GEORGE filed to sell 5,575 shares at $139.1.
May 16 '25
MASSARO GEORGE filed to sell 5,680 shares at $136.3.
May 16 '25
MASSARO GEORGE filed to sell 5,599 shares at $137.7.
May 16 '25
MASSARO GEORGE filed to sell 5,715 shares at $145.5.
May 15 '25
MASSARO GEORGE filed to sell 5,729 shares at $141.9.
May 15 '25

Congress Trading View All

Politician Filing Date Type Size
Rob Bresnahan
May 8, 25 Buy $15K - $50K
Julie Johnson
Feb 13, 25 Buy $1K - $15K
Ro Khanna
Dec 6, 24 Buy $1K - $15K

What is the Market Cap of Charles River Laboratories?

The Market Cap of Charles River Laboratories is $6.81B.

What is Charles River Laboratories' PE Ratio?

As of today, Charles River Laboratories' PE (Price to Earnings) ratio is 592.3.

What is the current stock price of Charles River Laboratories?

Currently, the price of one share of Charles River Laboratories stock is $136.25.

How can I analyze the CRL stock price chart for investment decisions?

The CRL stock price chart above provides a comprehensive visual representation of Charles River Laboratories' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Charles River Laboratories shares. Our platform offers an up-to-date CRL stock price chart, along with technical data analysis and alternative data insights.

Does CRL offer dividends to its shareholders?

As of our latest update, Charles River Laboratories (CRL) does not offer dividends to its shareholders. Investors interested in Charles River Laboratories should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Charles River Laboratories?

Some of the similar stocks of Charles River Laboratories are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Stock performance
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
Start typing below to begin.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.